EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Comparison of the efficacy, tolerability, and smoothness indexes of two nifedipine formulations: A randomized, double-dummy, double-blind, controlled trial



Comparison of the efficacy, tolerability, and smoothness indexes of two nifedipine formulations: A randomized, double-dummy, double-blind, controlled trial



Current Therapeutic Research 63(5): 305-315



Background: Nifedipine is an effective dihydropyridine calcium channel antagonist used in the treatment of high blood pressure (BP), although side effects related to its potency and short half-life have led to development of a sustained-release formulation, nifedipine gastrointestinal therapeutic system (N-GITS) with osmotic pump. Objective: This study compared the efficacy, tolerability, and smoothness indexes of 2 formulations of nifedipine-N-GITS and slow-release microgranules (N-MG)-in patients with hypertension. Methods: This was a randomized, double-dummy, double-blind, controlled trial in outpatients with mild to moderate essential hypertension (sitting diastolic BP (DBP) >90 and <115 mm Hg). Patients were randomized to receive either N-GITS 30 mg plus N-MG placebo or N-MG 30 mg plus N-GITS placebo once daily for 12 weeks. In patients who had not achieved adequate BP control (DBP <90 mm Hg or a decrease in DBP of >10 mm Hg compared with baseline) at week 3, the dose of the respective formulations was increased to 60 mg once daily for the remainder of the trial. The primary end point was change in mean BP over 24 hours. In addition, the smoothness indexes of both formulations were compared between groups to evaluate the homogeneity of their antihypertensive effects. Tolerability was assessed in terms of the incidence of adverse events. Results: Fifty-four outpatients (44 women, 10 men; mean age, 54 years) were enrolled, 26 in the N-GITS-treated group and 28 in the N-MG-treated group. A decrease in mean BP over 24 hours was observed in both groups, with no significant differences between groups. The N-GITS-treated group showed a slight but statistically significant increase in heart rate (HR) at 12 weeks (P=0.017); the N-MG-treated group showed a slight but statistically significant decrease in HR (P=0.03). Smoothness index values (mean+-SD) for active drug versus comparison-drug placebo in all patients (including nonresponders) were 0.466+-0.5 for the N-GITS-treated group and 0.459+-0.4 for the N-MG-treated group. The corresponding smoothness index values when nonresponders (N-GITS, 1 nonresponder, 25 responders; N-MG, 3 nonresponders, 25 responders) were excluded were 0.716+-0.5 and 0.707+-0.7, respectively. No statistically significant difference in smoothness index was found between the 2 groups. Conclusion: The results of this study suggest that N-GITS and N-MG have similar therapeutic effects and smoothness indexes.

(PDF emailed within 0-6 h: $19.90)

Accession: 010362686

Download citation: RISBibTeXText

DOI: 10.1016/s0011-393x(02)80034-0



Related references

Efficacy and Tolerability of Celecoxib versus Naproxen in Patients with Osteoarthritis of the Knee A Randomized, Double-Blind, Double-Dummy Trial. Journal of International Medical Research 40(4): 1357-1370, 2012

Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial. Journal of International Medical Research 40(4): 1357-1370, 2013

Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study. Journal of Headache and Pain 13(8): 669-675, 2013

Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack a randomized, double-blind, double-dummy, cross-over study. 2012

Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial. Clinical Therapeutics 32(11): 1896-1905, 2011

The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: A randomized, double-blind, active-controlled, double-dummy trial. Current Therapeutic Research 63(9): 606-620, September, 2002

Efficacy and safety of carbetocin given as an intravenous bolus compared with short infusion for Caesarean section - double-blind, double-dummy, randomized controlled non-inferiority trial. British Journal of Anaesthesia 118(5): 772-780, 2017

Treatment of acute hepatic encephalopathy with rifaximin in comparison with lactitol A multi-centre, double-blind, double-dummy, randomized controlled trial. Journal of Hepatology 30(SUPPL 1): 81, 1999

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. Journal of Hepatology 38(1): 51-58, 2002

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. Journal of Hepatology 38(1): 51-58, January, 2003

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes, Obesity & Metabolism 18(12): 1191-1198, 2016

Efficacy and Safety of Zhuanggu Joint Capsules in Combination with Celecoxib in Knee Osteoarthritis: A Multi-center, Randomized, Double-blind, Double-dummy, and Parallel Controlled Trial. Chinese Medical Journal 129(8): 891-897, 2016

A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. Journal of Pain and Symptom Management 40(2): 266-278, 2010

A Randomized, Double-Blind, Double-Dummy Comparison of the Efficacy and Tolerability of Low-Dose Transdermal Buprenorphine (BuTrans Seven-Day Patches) With Buprenorphine Sublingual Tablets (Temgesic) in Patients With Osteoarthritis Pain. Yearbook of Anesthesiology and Pain Management 2011: 350-351, 2011

Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clinical Infectious Diseases 55(1): 82-88, 2012